Anthony Mirhaydari

Anthony Mirhaydari

Anthony Mirhaydari is founder of the Edge and Edge Pro investment advisory newsletters.

He is an independent investment columnist with work appearing at Investorplace, The Fiscal Times, CBS News MoneyWatch, MSN Money, Yahoo Finance, and Dow Jones MarketWatch. He started covering the markets and the economy in the media in 2008 in the midst of the greatest financial crisis in generations.

Previously, he was a senior research analyst with Markman Capital Insight, an advisory and money management firm, and a business consulting analyst with Moss Adams focusing on the financial-services industry.

Recent Articles

Smart Investors, Keep an Eye on the VIX

For the first time ever, the Dow Jones closed above the 26,000 level, dismissing Tuesday's intra-day selloff as if it never happened.

5 Blue-Chip Stocks That Are a Threat to the Dow

These five blue-chip stocks continue to threaten the Dow Jones' chances of maintaining 26,000. Here's what investors need to know.

Watch out for a Nasty Market Pullback

Stocks suffered their worst one-day reversal since June 2016 shortly after the Dow Jones zoomed past the 26,000 today.

The VIX Is Dangerously Close to a Tipping Point

Stocks soared on Thursday thanks to the largest gain by transportation stocks since 2001 and a rally in Treasury bonds.

7 High-Risk, High-Reward Stocks to Buy Now

The potential of these high-reward stocks to buy could outweigh the risks. Here's what investors need to keep in mind when looking at these stocks.

Wall Street Shudders on China Bond Worries

Stocks slipped at the open on Wednesday before recovering in mid-day trading. But it wasn't enough to stop the New Years rally from ending.

Treasury Bond Yield Pushes Ahead of the S&P 500

There has never been a day like Tuesday -- new high, poor breadth, rising VIX -- since the data started being collected.

Stocks Set for Record Run as Risks Multiply

Stocks are set to keep running higher, but that doesn't mean all the risks have disappeared. Here's what investors need to know.

Stocks Set for a Record Run as Risks Multiply 

Analysts say it looks like stocks could be headed for a 'melt-up' scenario.

5 Biotech Stocks That Must Be Quarantined

A number of biotech stocks in the sector look vulnerable to further profit-taking losses. Here are five to watch.